Advertisement
ARAY vs BNGO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a StrongBuy and BNGO is a Hold.
ARAY's RSI Oscillator dives oversold zone
The RSI Indicator for ARAY moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ARAY just turned positive on November 02, 2026. Looking at past instances where ARAY's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
ARAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARAY as a result. In 85 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
ARAY moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARAY crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ARAY entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.315) is normal, around the industry mean (4.142). P/E Ratio (-0.275) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ARAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BNGO's Indicator enters downward trend
The Aroon Indicator for BNGO entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 321 similar instances where the Aroon Indicator formed such a pattern. In 299 of the 321 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Oscillator exited the oversold zone, 35 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 66 cases where BNGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNGO as a result. In 67 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 165 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (4.964). P/E Ratio (-0.382) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARAY | BNGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 95 | 72 | |
P/E GROWTH RATING 1..100 | 9 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNGO's Valuation (30) in the Biotechnology industry is in the same range as ARAY (62) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
BNGO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARAY (100) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
BNGO's SMR Rating (98) in the Biotechnology industry is in the same range as ARAY (98) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
BNGO's Price Growth Rating (72) in the Biotechnology industry is in the same range as ARAY (95) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
ARAY's P/E Growth Rating (9) in the Medical Specialties industry is significantly better than the same rating for BNGO (100) in the Biotechnology industry. This means that ARAY’s stock grew significantly faster than BNGO’s over the last 12 months.
| ARAY | BNGO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 85% | 3 days ago 70% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 80% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 78% |
| MACD ODDS (%) | 3 days ago 73% | N/A |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 79% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 90% |
| Advances ODDS (%) | N/A | 6 days ago 77% |
| Declines ODDS (%) | 3 days ago 86% | 4 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 81% | 3 days ago 80% |
| Aroon ODDS (%) | 3 days ago 84% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARAY’s FA Score shows that 1 FA rating(s) are green while BNGO’s FA Score has 1 green FA rating(s).
- ARAY’s FA Score: 1 green, 4 red.
- BNGO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARAY’s TA Score shows that 4 TA indicator(s) are bullish while BNGO’s TA Score has 5 bullish TA indicator(s).
- ARAY’s TA Score: 4 bullish, 5 bearish.
- BNGO’s TA Score: 5 bullish, 4 bearish.
Price Growth
ARAY (@Medical/Nursing Services) experienced а -21.43% price change this week, while BNGO (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.17%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +12.16%.
Reported Earning Dates
ARAY is expected to report earnings on Jan 27, 2027.
BNGO is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.17% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ARAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with ILMN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then ILMN could also see price increases.
| Ticker / NAME | Correlation To ARAY | 1D Price Change % | ||
|---|---|---|---|---|
| ARAY | 100% | -11.22% | ||
| ILMN - ARAY | 41% Loosely correlated | +2.47% | ||
| A - ARAY | 41% Loosely correlated | +1.73% | ||
| ICUI - ARAY | 40% Loosely correlated | +2.66% | ||
| NVST - ARAY | 39% Loosely correlated | +0.84% | ||
| WRBY - ARAY | 38% Loosely correlated | -2.30% | ||
More | ||||
BNGO and
Correlation & Price change
A.I.dvisor tells us that BNGO and RGEN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNGO and RGEN's prices will move in lockstep.
| Ticker / NAME | Correlation To BNGO | 1D Price Change % | ||
|---|---|---|---|---|
| BNGO | 100% | +4.55% | ||
| RGEN - BNGO | 30% Poorly correlated | +2.97% | ||
| ARAY - BNGO | 30% Poorly correlated | -11.22% | ||
| PACB - BNGO | 29% Poorly correlated | -7.20% | ||
| VIVO - BNGO | 29% Poorly correlated | +8.74% | ||
| DRIO - BNGO | 28% Poorly correlated | -11.71% | ||
More | ||||